Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (<scp>AWARD</scp>‐5)Zachary Skrivanek, Donald A. Berry, James H. Anderson et al.|Diabetes Obesity and Metabolism|2014Cited by 72
An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline CharacteristicsMary Jane Geiger, James H. Anderson, Zachary Skrivanek et al.|Journal of Diabetes Science and Technology|2012Cited by 40
Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and SimulationsZachary Skrivanek, Brenda Gaydos, James H. Anderson et al.|Journal of Diabetes Science and Technology|2012Cited by 33
Using Lock Servers to Scale Real-Time Locking Protocols: Chasing Ever-Increasing Core CountsCatherine E. Nemitz, James H. Anderson|DROPS (Schloss Dagstuhl – Leibniz Center for Informatics)|2018Cited by 9